BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen Y, Kornblit B, Hamlin DK, Sale GE, Santos EB, Wilbur DS, Storer BE, Storb R, Sandmaier BM. Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation. Blood 2012;119:1130-8. [PMID: 22134165 DOI: 10.1182/blood-2011-09-380436] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Jurcic JG. Targeted Alpha-Particle Therapy for Hematologic Malignancies. Semin Nucl Med 2020;50:152-61. [PMID: 32172800 DOI: 10.1053/j.semnuclmed.2019.09.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
2 Kornblit B, Chen Y, Sandmaier BM. Conditioning with α-emitter based radioimmunotherapy in canine allogeneic hematopoietic cell transplantation. Chimerism 2012;3:40-2. [PMID: 22772070 DOI: 10.4161/chim.20726] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
3 Granot N, Storer BE, Cooper JP, Flowers ME, Sandmaier BM, Storb R. Allogeneic Hematopoietic Cell Transplantation in the Outpatient Setting. Biol Blood Marrow Transplant 2019;25:2152-9. [PMID: 31255743 DOI: 10.1016/j.bbmt.2019.06.025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
4 Li Y, Hamlin DK, Chyan MK, Morscheck TM, Ferrier MG, Wong R, Wilbur DS. Investigation of a tellurium-packed column for isolation of astatine-211 from irradiated bismuth targets and demonstration of a semi-automated system. Sci Rep 2019;9:16960. [PMID: 31740701 DOI: 10.1038/s41598-019-53385-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
5 Seidl C. Radioimmunotherapy with α-particle-emitting radionuclides. Immunotherapy 2014;6:431-58. [DOI: 10.2217/imt.14.16] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.5] [Reference Citation Analysis]
6 Monaco F, Scott BL, Chauncey TR, Petersen FB, Storer BE, Baron F, Flowers ME, Deeg HJ, Maloney DG, Storb R, Sandmaier BM. Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms. Haematologica 2019;104:1221-9. [PMID: 30630975 DOI: 10.3324/haematol.2018.199398] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
7 Sato M, Storb R, Loretz C, Stone D, Mielcarek M, Sale GE, Rezvani AR, Graves SS. Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target. Transplantation 2013;96:34-41. [PMID: 23694952 DOI: 10.1097/TP.0b013e318295c025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
8 Castiello MC, Bosticardo M, Sacchetti N, Calzoni E, Fontana E, Yamazaki Y, Draghici E, Corsino C, Bortolomai I, Sereni L, Yu HH, Uva P, Palchaudhuri R, Scadden DT, Villa A, Notarangelo LD. Efficacy and safety of anti-CD45-saporin as conditioning agent for RAG deficiency. J Allergy Clin Immunol 2021;147:309-320.e6. [PMID: 32387109 DOI: 10.1016/j.jaci.2020.04.033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
9 Ali AM, Dehdashti F, DiPersio JF, Cashen AF. Radioimmunotherapy-based conditioning for hematopoietic stem cell transplantation: Another step forward. Blood Rev 2016;30:389-99. [PMID: 27174151 DOI: 10.1016/j.blre.2016.04.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
10 Logan AC, Weissman IL, Shizuru JA. The road to purified hematopoietic stem cell transplants is paved with antibodies. Curr Opin Immunol 2012;24:640-8. [PMID: 22939368 DOI: 10.1016/j.coi.2012.08.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
11 Jurcic JG, Rosenblat TL. Targeted alpha-particle immunotherapy for acute myeloid leukemia. Am Soc Clin Oncol Educ Book 2014;:e126-31. [PMID: 24857092 DOI: 10.14694/EdBook_AM.2014.34.e126] [Cited by in Crossref: 44] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
12 Storb R, Sandmaier BM. Nonmyeloablative allogeneic hematopoietic cell transplantation. Haematologica 2016;101:521-30. [PMID: 27132278 DOI: 10.3324/haematol.2015.132860] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
13 Storb R. HSCT: Historical Perspective. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook. Cham: Springer International Publishing; 2019. pp. 3-9. [DOI: 10.1007/978-3-030-02278-5_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Hill GR, Koyama M. Cytokines and costimulation in acute graft-versus-host disease. Blood 2020;136:418-28. [PMID: 32526028 DOI: 10.1182/blood.2019000952] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
15 Griffith LM, Cowan MJ, Notarangelo LD, Kohn DB, Puck JM, Pai SY, Ballard B, Bauer SC, Bleesing JJ, Boyle M, Brower A, Buckley RH, van der Burg M, Burroughs LM, Candotti F, Cant AJ, Chatila T, Cunningham-Rundles C, Dinauer MC, Dvorak CC, Filipovich AH, Fleisher TA, Bobby Gaspar H, Gungor T, Haddad E, Hovermale E, Huang F, Hurley A, Hurley M, Iyengar S, Kang EM, Logan BR, Long-Boyle JR, Malech HL, McGhee SA, Modell F, Modell V, Ochs HD, O'Reilly RJ, Parkman R, Rawlings DJ, Routes JM, Shearer WT, Small TN, Smith H, Sullivan KE, Szabolcs P, Thrasher A, Torgerson TR, Veys P, Weinberg K, Zuniga-Pflucker JC; workshop participants. Primary Immune Deficiency Treatment Consortium (PIDTC) report. J Allergy Clin Immunol 2014;133:335-47. [PMID: 24139498 DOI: 10.1016/j.jaci.2013.07.052] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
16 Teze D, Sergentu DC, Kalichuk V, Barbet J, Deniaud D, Galland N, Maurice R, Montavon G. Targeted radionuclide therapy with astatine-211: Oxidative dehalogenation of astatobenzoate conjugates. Sci Rep 2017;7:2579. [PMID: 28566709 DOI: 10.1038/s41598-017-02614-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
17 Nakaya A, Qiu H, Santos EB, Hamlin DK, Wilbur DS, Storb R, Sandmaier BM. Addition of Astatine-211-Labeled Anti-CD45 Antibody to TBI as Conditioning for DLA-Identical Marrow Transplantation: A Novel Strategy to Overcome Graft Rejection in a Canine Presensitization Model: "Radioimmunotherapy to Overcome Transfusion-Induced Sensitization". Transplant Cell Ther 2021;27:476.e1-7. [PMID: 33775618 DOI: 10.1016/j.jtct.2021.02.018] [Reference Citation Analysis]
18 Koyama M, Hill GR. The primacy of gastrointestinal tract antigen-presenting cells in lethal graft-versus-host disease. Blood. 2019;134:2139-2148. [PMID: 31697827 DOI: 10.1182/blood.2019000823] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
19 Mawad R, Gooley TA, Rajendran JG, Fisher DR, Gopal AK, Shields AT, Sandmaier BM, Sorror ML, Deeg HJ, Storb R, Green DJ, Maloney DG, Appelbaum FR, Press OW, Pagel JM. Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome. Biol Blood Marrow Transplant 2014;20:1363-8. [PMID: 24858425 DOI: 10.1016/j.bbmt.2014.05.014] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 4.5] [Reference Citation Analysis]
20 Graves SS, Storb R. Developments and translational relevance for the canine haematopoietic cell transplantation preclinical model. Vet Comp Oncol 2020;18:471-83. [PMID: 32385957 DOI: 10.1111/vco.12608] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Wilbur DS, Chyan MK, Nakamae H, Chen Y, Hamlin DK, Santos EB, Kornblit BT, Sandmaier BM. Reagents for astatination of biomolecules. 6. An intact antibody conjugated with a maleimido-closo-decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato-closo-decaborate(2-) reagent via lysine amines. Bioconjug Chem 2012;23:409-20. [PMID: 22296587 DOI: 10.1021/bc200401b] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 4.7] [Reference Citation Analysis]
22 Servais S, Beguin Y, Baron F. Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation. Expert Opinion on Emerging Drugs 2013;18:173-92. [DOI: 10.1517/14728214.2013.798642] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
23 Graves SS, Parker MH, Storb R. Animal Models for Preclinical Development of Allogeneic Hematopoietic Cell Transplantation. ILAR J 2018;59:263-75. [PMID: 30010833 DOI: 10.1093/ilar/ily006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
24 Jurcic JG. Radioimmunotherapy for hematopoietic cell transplantation. Immunotherapy 2013;5:383-94. [PMID: 23557421 DOI: 10.2217/imt.13.11] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
25 Kornblit B, Maloney DG, Storb R, Storek J, Hari P, Vucinic V, Maziarz RT, Chauncey TR, Pulsipher MA, Bruno B, Petersen FB, Bethge WA, Hübel K, Bouvier ME, Fukuda T, Storer BE, Sandmaier BM. Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial. Biol Blood Marrow Transplant 2013;19:1340-7. [PMID: 23769990 DOI: 10.1016/j.bbmt.2013.06.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
26 Garcia-Perez L, van Roon L, Schilham MW, Lankester AC, Pike-Overzet K, Staal FJT. Combining Mobilizing Agents with Busulfan to Reduce Chemotherapy-Based Conditioning for Hematopoietic Stem Cell Transplantation. Cells 2021;10:1077. [PMID: 33946560 DOI: 10.3390/cells10051077] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Li Y, Hamlin DK, Chyan MK, Wong R, Dorman EF, Emery RC, Woodle DR, Manger RL, Nartea M, Kenoyer AL, Orozco JJ, Green DJ, Press OW, Storb R, Sandmaier BM, Wilbur DS. cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignancies. PLoS One 2018;13:e0205135. [PMID: 30335787 DOI: 10.1371/journal.pone.0205135] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
28 Villa A, Capo V, Castiello MC. Innovative Cell-Based Therapies and Conditioning to Cure RAG Deficiency. Front Immunol 2020;11:607926. [PMID: 33329604 DOI: 10.3389/fimmu.2020.607926] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Cowan MJ, Dvorak CC, Long-Boyle J. Opening Marrow Niches in Patients Undergoing Autologous Hematopoietic Stem Cell Gene Therapy. Hematol Oncol Clin North Am 2017;31:809-22. [PMID: 28895849 DOI: 10.1016/j.hoc.2017.06.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
30 Frost SH, Miller BW, Bäck TA, Santos EB, Hamlin DK, Knoblaugh SE, Frayo SL, Kenoyer AL, Storb R, Press OW, Wilbur DS, Pagel JM, Sandmaier BM. α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation. J Nucl Med 2015;56:1766-73. [PMID: 26338894 DOI: 10.2967/jnumed.115.162388] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
31 Burtner CR, Chandrasekaran D, Santos EB, Beard BC, Adair JE, Hamlin DK, Wilbur DS, Sandmaier BM, Kiem HP. (211)Astatine-Conjugated Monoclonal CD45 Antibody-Based Nonmyeloablative Conditioning for Stem Cell Gene Therapy. Hum Gene Ther 2015;26:399-406. [PMID: 25919226 DOI: 10.1089/hum.2015.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
32 Teiluf K, Seidl C, Blechert B, Gaertner FC, Gilbertz KP, Fernandez V, Bassermann F, Endell J, Boxhammer R, Leclair S, Vallon M, Aichler M, Feuchtinger A, Bruchertseifer F, Morgenstern A, Essler M. α-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma. Oncotarget 2015;6:4692-703. [PMID: 25576914 DOI: 10.18632/oncotarget.2986] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 5.5] [Reference Citation Analysis]
33 Palchaudhuri R, Saez B, Hoggatt J, Schajnovitz A, Sykes DB, Tate TA, Czechowicz A, Kfoury Y, Ruchika F, Rossi DJ, Verdine GL, Mansour MK, Scadden DT. Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin. Nat Biotechnol 2016;34:738-45. [PMID: 27272386 DOI: 10.1038/nbt.3584] [Cited by in Crossref: 104] [Cited by in F6Publishing: 93] [Article Influence: 17.3] [Reference Citation Analysis]
34 Graves SS, Storb R. Evolution of haematopoietic cell transplantation for canine blood disorders and a platform for solid organ transplantation. Vet Med Sci 2021. [PMID: 34390541 DOI: 10.1002/vms3.601] [Reference Citation Analysis]